Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
revised:
29
04
2024
received:
07
11
2023
accepted:
12
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
28
5
2024
Statut:
aheadofprint
Résumé
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post-HCT, but published clinical experience is primarily with the first-generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second-generation TKI (2G-TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty-six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G-TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G-TKI: 576.0 days (range, 72-921) versus 254.5 days (range, 3-2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5-year overall survival and progression-free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post-HCT TKI maintenance in a large real-world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15(2):67‐75. doi:10.1200/jop.18.00271
Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome‐positive acute lymphocytic leukemia with hyper‐CVAD and imatinib mesylate. Blood. 2004;103(12):4396‐4407. doi:10.1182/blood‐2003‐08‐2958
Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR‐ABL‐positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460‐466. doi:10.1200/jco.2005.03.2177
Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia‐positive acute lymphoblastic leukemia. Blood. 2015;126(6):746‐756. doi:10.1182/blood‐2015‐03‐636548
Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced‐intensity chemotherapy combined with imatinib in adults with Ph‐positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711‐3719. doi:10.1182/blood‐2015‐02‐627935
Rousselot P, Coude MM, Gokbuget N, et al. Dasatinib and low‐intensity chemotherapy in elderly patients with Philadelphia chromosome‐positive ALL. Blood. 2016;128(6):774‐782. doi:10.1182/blood‐2016‐02‐700153
Foà R, Vitale A, Vignetti M, et al. Dasatinib as first‐line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521‐6528. doi:10.1182/blood‐2011‐05‐351403
Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long‐term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843‐850. doi:10.1182/blood‐2013‐09‐529008
Ravandi F, O'Brien SM, Cortes JE, et al. Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia. Cancer. 2015;121:4158‐4164. doi:10.1002/cncr.29646
Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper‐CVAD with ponatinib as first‐line therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: long‐term follow‐up of a single‐centre, phase 2 study. Lancet Haematol. 2018;5(12):e618‐e627. doi:10.1016/s2352‐3026(18)30176‐5
Foà R, Bassan R, Vitale A, et al. Dasatinib–blinatumomab for Ph‐positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613‐1623. doi:10.1056/NEJMoa2016272
Ravandi F, Othus M, O'Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1(3):250‐259. doi:10.1182/bloodadvances.2016001495
Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre‐imatinib era: results from the international ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489‐4496. doi:10.1182/blood‐2009‐01‐199380
Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia–results of the prospective multicenter LALA‐94 trial. Blood. 2002;100(7):2357‐2366. doi:10.1182/blood‐2002‐03‐0704
Warraich Z, Tenneti P, Thai T, et al. Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for philadelphia chromosome–positive acute lymphoblast leukemia: a systematic review. Biol Blood Marrow Transplant. 2020;26(3):e55‐e64. doi:10.1016/j.bbmt.2019.09.022
Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease‐triggered imatinib after allogeneic stem cell transplantation for BCR‐ABL1‐positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254‐1262. doi:10.1038/leu.2012.352
Kebriaei P, Saliba R, Rondon G, et al. Long‐term follow‐up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18(4):584‐592. doi:10.1016/j.bbmt.2011.08.011
Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high‐risk Philadelphia chromosome‐positive leukemia. Blood. 2007;109(7):2791‐2793. doi:10.1182/blood‐2006‐04‐019836
Chen H, Liu KY, Xu LP, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease‐free survival for patients with Philadelphia chromosome‐positive acute lymphobla stic leukemia. J Hematol Oncol. 2012;5:29. doi:10.1186/1756‐8722‐5‐29
Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95(1):87‐95. doi:10.3324/haematol.2009.011221
Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122(19):2941‐2951. doi:10.1002/cncr.30130
Lee SJ. Classification systems for chronic graft‐versus‐host disease. Blood. 2017;129(1):30‐37. doi:10.1182/blood‐2016‐07‐686642
Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628‐1633. doi:10.1016/j.bbmt.2009.07.004
Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper‐CVAD for the front‐line treatment of adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653‐661. doi:10.3324/haematol.2014.118588
Ottmann OG. TKI vs relapse after HSCT: is the jury still out? Blood. 2020;136(15):1705‐1706. doi:10.1182/blood.2020007021
Ron R, Rainer S, Brenda MS, et al. Non‐myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high‐risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113‐1120. doi:10.3324/haematol.2011.040261
Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106(2):458‐463. doi:10.1182/blood‐2004‐05‐1746
Saini N, Marin D, Ledesma C, et al. Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL. Blood. 2020;136(15):1786‐1789. doi:10.1182/blood.2019004685
DeFilipp Z, Ancheta R, Liu Y, et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020;26(3):472‐479. doi:10.1016/j.bbmt.2019.10.017
Aldoss I, Gaal K, Al Malki MM, et al. Dasatinib‐induced colitis after allogeneic stem cell transplantation for Philadelphia chromosome‐positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22(10):1900‐1903. doi:10.1016/j.bbmt.2016.06.022
Sung AD, Chao NJ. Concise review: acute graft‐versus‐host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013;2(1):25‐32. doi:10.5966/sctm.2012‐0115
Chen H, Xu L‐P, Zhang X‐H, et al. Safety and outcomes of maintenance therapy with third‐generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930. doi:10.1016/j.leukres.2022.106930
Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft‐versus‐host disease. Blood. 2009;114(3):719‐722. doi:10.1182/blood‐2009‐02‐204750
Chen GL, Arai S, Flowers ME, et al. A phase 1 study of imatinib for corticosteroid‐dependent/refractory chronic graft‐versus‐host disease: response does not correlate with anti‐PDGFRA antibodies. Blood. 2011;118(15):4070‐4078. doi:10.1182/blood‐2011‐03‐341693
Sánchez‐Ortega I, Servitje O, Arnan M, et al. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2012;18(2):318‐323. doi:10.1016/j.bbmt.2011.10.042
Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol. 2012;24(2):191‐196. doi:10.1097/CCO.0b013e32834f5c27
Holtan SG, Versluis J, Weisdorf DJ, Cornelissen JJ. Optimizing donor choice and GVHD prophylaxis in allogeneic hematopoietic cell transplantation. J Clin Oncol. 2021;39(5):373‐385. doi:10.1200/jco.20.01771
Chhabra S, Ahn KW, Hu Z‐H, et al. Myeloablative vs reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018;2(21):2922‐2936. doi:10.1182/bloodadvances.2018024844
Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a US, single‐centre, single‐arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24‐e34. doi:10.1016/s2352‐3026(22)00319‐2
Kantarjian H, Short NJ, Jain N, et al. Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results. Am J Hematol. 2023;98(3):493‐501. doi:10.1002/ajh.26816
Short NJ, Jabbour E, Macaron W, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT‐PCR for BCR::ABL1. Am J Hematol. 2023;98(8):1196‐1203. doi:10.1002/ajh.26949
Ismail SI, Naffa RG, Yousef AM, Ghanim MT. Incidence of bcr‐abl fusion transcripts in healthy individuals. Mol Med Rep. 2014;9(4):1271‐1276. doi:10.3892/mmr.2014.1951
Nishiwaki S, Kim JH, Ito M, et al. Multi‐lineage BCR‐ABL expression in Philadelphia chromosome‐positive acute lymphoblastic leukemia is associated with improved prognosis but no specific molecular features. Front Oncol. 2020;10:586567. doi:10.3389/fonc.2020.586567
Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR::ABL1‐positive acute lymphoblastic leukemia: different significance in typical ALL and in CML‐like disease. Leukemia. 2022;36(12):2793‐2801. doi:10.1038/s41375‐022‐01668‐0